Analysts Raise Bar on Vertex, Eye Homebuilders
Vertex Pharmaceuticals drew two bullish calls on Wednesday. UBS analyst Michael Yee lifted his target to $640. TD Cowen's Phil Nadeau followed at $575, up from $550. Both rate the stock Buy. The consensus target now…